Date: June. 15th, 2022 Your Name:_Rocco Morra

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	ial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

	Payment or honoraria for	X None	14 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
	Payment for expert	XNone		
	testimony			
7	Support for attending	XNone		
	meetings and/or travel			3327
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	X None		
	Participation on a Data Safety Monitoring Board or			
	Advisory Board		State of the	
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	XNone		
		- 20-47-		
12	Receipt of equipment,	X_None		
	materials, drugs, medical			N. N. S.
	writing, gifts or other			
	services			
13	Other financial or non-	XNone	attaus (200)	
	financial interests			APPENDING SELECTION

None.			

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Company of the questions on this form.

Date: June. 15th, 2022

Your Name:_Antonio D'Ambrosio

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	ial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_X_None	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	_X_None	
4	Consulting fees	XNone	

	Payment or honoraria for .	X None	THE RESIDENCE OF SECULO		
	lectures, presentations,	X_None	enteriorista. New Control of the Co		10.62
	speakers bureaus, manuscript writing or educational events				
	Payment for expert testimony	XNone			
	Support for attending meetings and/or travel	XNone			
		y ed a see	1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -		
	Patents planned, issued or pending	XNone			
1	Participation on a Data	XNone			
	Safety Monitoring Board or Advisory Board				
.0	Leadership or fiduciary role in other board, society,	XNone			
	committee or advocacy group, paid or unpaid				
1	Stock or stock options	XNone			
				er og det er og	
2	Receipt of equipment,	X_None		77-7-6-1-2	
	materials, drugs, medical writing, gifts or other services				
3	Other financial or non- financial interests	XNone		Travel Long	

None		
None.		

Please place an "X" next to the following statement to indicate your agreement:

Date: June. 15th, 2022

Your Name:_Erica Pietroluongo

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		whom	all entities with you have this onship or indicate (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time	frame: Since the initi	al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	_x_	None	
		The state of	Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_	None	
3	Royalties or licenses	x	None	
4	Consulting fees	_x_	_None	

Payment or honoraria for lectures, presentations,	XNone	
speakers bureaus, manuscript writing or educational events		
Payment for expert testimony	XNone	
Support for attending meetings and/or travel	XNone	
A STATE OF THE STA		
Patents planned, issued or pending	XNone	
Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
Stock or stock options	XNone	
Receipt of equipment, materials, drugs, medical	X_None	
writing, gifts or other services		
Other financial or non- financial interests	XNone	
	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non-	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- X_None

None.			

Please place an "X" next to the following statement to indicate your agreement:

Date: June. 15th, 2022

Your Name:_Pietro De Placido

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

***		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
	The second second	Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

	5	V N	
5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus, manuscript writing or educational events		
5	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	The Control of the Co
	[10] 사이스 아니아 [20] [24] [11] 이동시 [20] [20] [20] [20] [20] [20] [20] [20]		A 100
10	Safety Monitoring Board or Advisory Board Leadership or fiduciary role	XNone	the Charles of the State of the
	in other board, society, committee or advocacy group, paid or unpaid		
11	Stock or stock options	XNone	
		•	Company of the Compan
12	Receipt of equipment,	X_None	
	materials, drugs, medical writing, gifts or other services		
13	Other financial or non-	XNone	
	financial interests		

Please place an "X" next to the following statement to indicate your agreement:

Date: June. 15th, 2022

Your Name:_Liliana Montella

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

		THE STATE OF THE STATE OF		
	Payment or honoraria for	X None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	X None		
	testimony			
7	Support for attending	X None	o reeds	
	meetings and/or travel			
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	X None		Note that the second of the se
	Safety Monitoring Board or			A CONTRACTOR OF THE PROPERTY O
	Advisory Board			
10	Leadership or fiduciary role	X None		
	in other board, society,			
	committee or advocacy	Name of the second		
	group, paid or unpaid			
11	Stock or stock options	X None	Part Provide	
	Stock of Stock options		1400	
	and the second of the second			A STATE OF THE STA
12	Paraint of aguinment	X None		
12	Receipt of equipment, materials, drugs, medical	X_INOTIE		
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests	4.00	Section of the sectio	

None.	1			
		1 1		

Please place an "X" next to the following statement to indicate your agreement:

Date: June. 15th, 2022

Your Name:_Vitantonio Del Deo

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	ial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
1	and the second s	Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

100			A COST OF THE PROPERTY OF	
5	Payment or honoraria for	XNone		
	lectures, presentations, speakers bureaus, manuscript writing or educational events			
	Payment for expert testimony	XNone		
	Support for attending meetings and/or travel	XNone		
	Patents planned, issued or pending	XNone		
	Participation on a Data Safety Monitoring Board or	X_None		
0	Advisory Board Leadership or fiduciary role	X None	9 7 5 5d	
u	in other board, society,	XNone		(*
	committee or advocacy group, paid or unpaid			
1	Stock or stock options	XNone	A KEARS	
		100 mm mm 200 1 mm m m m m m m m m m m m m m m m m m		A CONTRACTOR OF THE PROPERTY O
2	Receipt of equipment,	X_None		1
	materials, drugs, medical writing, gifts or other services			
3.	Other financial or non-	XNone	Jan C.	
	financial interests			
21.15		TO THAIRM X		

Please place an "X" next to the following statement to indicate your agreement:

None.

Date: June. 15th, 2022

Your Name: Marianna Tortora

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	lectures, presentations,	XNone		
	speakers bureaus, manuscript writing or educational events			
6	Payment for expert testimony	XNone		
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or pending	XNone		
9	Participation on a Data	XNone		
	Safety Monitoring Board or Advisory Board		N N N N N N N N N N N N N N N N N N N	
10	Leadership or fiduciary role in other board, society, committee or advocacy	XNone		
	group, paid or unpaid			
11	Stock or stock options	XNone		
12	Receipt of equipment,	X_None		
	materials, drugs, medical writing, gifts or other services			
13	Other financial or non- financial interests	XNone		
		analis Collins		The second secon

None.	

Please place an "X" next to the following statement to indicate your agreement:

Date: June. 15th, 2022 Your Name: Elide Matano

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus, manuscript writing or educational events	- H		
	Payment for expert testimony	XNone	31.50	
	testimony			
	Support for attending meetings and/or travel	XNone		
	, and a second			
	Patents planned, issued or	XNone		
	pending			
	Participation on a Data Safety Monitoring Board or Advisory Board	XNone		
0	Leadership or fiduciary role	XNone		4077270
	in other board, society, committee or advocacy group, paid or unpaid			
11	Stock or stock options	XNone		The Marine Committee of the Committee of
				A CONTRACT C
2	Receipt of equipment,	X_None		
	materials, drugs, medical			
	writing, gifts or other services			
3	Other financial or non-	XNone	1000	
	financial interests			

Date: June. 15th, 2022

Your Name: Vincenzo Damiano

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

F	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
and the same	educational events			The Advisor Cartina Control of Control of State Control
	Payment for expert	X_None		
1	estimony			
9	Support for attending	X None		
	meetings and/or travel			
1	Patents planned, issued or	XNone		
1	pending			
1	Participation on a Data	X_None		
	Safety Monitoring Board or	4		
100	Advisory Board	ELEPSONIES NO		
	Leadership or fiduciary role	X_None		
	n other board, society,			
	committee or advocacy group, paid or unpaid			
	Stock or stock options	X None	1.5-660	
1 :	Stock of Stock options	NORE		
2	Receipt of equipment,	X None		
	materials, drugs, medical			
	writing, gifts or other	7		
1	services			
3 (Other financial or non-	XNone	A species	
1	financial interests			

Please place an "X" next to the following statement to indicate your agreement:

Date: June. 15th, 2022

Your Name: Giovannella Palmieri

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	ial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

	Payment or honoraria for	XNone	
	lectures, presentations, speakers bureaus, manuscript writing or educational events		
	Payment for expert testimony	XNone	
7	Support for attending meetings and/or travel	_X_None	
3	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	_X_None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None	
13	Other financial or non- financial interests	_X_None	

None.			

Please place an "X" next to the following statement to indicate your agreement:

form A	question and			
om.				
form. Seun 6				
11111				
Jan 15				

Date: June. 15th, 2022

Your Name: Sabino De Placido

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	ial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	Celgene, Astrazeneca, Novartis, Pfizer, Roche	

	Payment or honoraria for	Celgene, Astrazeneca,	
5	lectures, presentations, speakers bureaus, manuscript writing or educational events	Novartis, Pfizer, Roche	
	Payment for expert	X None	
6	testimony	_x_rene	
7	Support for attending meetings and/or travel	X_None	
3	Patents planned, issued or	XNone	
	pending		
		The second secon	
	Participation on a Data Safety Monitoring Board or Advisory Board	X_None	
0	Leadership or fiduciary role in other board, society, committee or advocacy	X_None	
1	group, paid or unpaid	X None	A STATE OF THE SECOND STAT
11	Stock or stock options	_ X_None	
2	Receipt of equipment, materials, drugs, medical	X_None	
	writing, gifts or other services		
2	Other financial or non-	X None	
13	financial interests		
	Tilliancid interests		

form.

Date: June. 15th, 2022 Your Name: Mario Giuliano

Manuscript Title: The unusual first sign of presentation of renal cell carcinoma: a rare case report

Manuscript number (if known): ACR-22-16CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: pa	st 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	Lilly, Celgene, Novartis, Pfizer	

		I a series de la companya del companya de la companya del companya de la companya
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	Lilly, Celgene, Novartis, Pfizer, Istituto Gentili, Eisai Europe Ltd, Roche
6	Payment for expert testimony	X_None
7.	Support for attending meetings and/or travel	Novartis, Pfizer, Roche
8	Patents planned, issued or pending	XNone
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	XNone
11	Stock or stock options	_X_None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	X_None
13	Other financial or non- financial interests	X_None

Consulting or advisory role: Lilly, Celgene, Novartis, Pfizer

Speaker's Bureau: Lilly, Celgene, Novartis, Pfizer, Istituto Gentili, Eisai Europe Ltd, Roche

Travel, Accomodation, expenses: Novartis, Pfizer, Roche

Please place an "X" next to the following statement to indicate your agreement: